Skip to Content
  • 3.5
    Impact Factor
  • 5.5
    CiteScore
  • 30 days
    Submission to First Decision
  • 5 days
    Acceptance to Publication

International Journal of Neonatal Screening

International Journal of Neonatal Screening (IJNS) is an international, peer-reviewed, open access journal on neonatal screening and neonatal medicine, published quarterly online. It is the official journal of the International Society for Neonatal Screening (ISNS). The German Society for Neonatal Screening (DGNS), French Society for Neonatal Screening (SFDN), Japanese Society for Neonatal Screening (JSNS), UK Newborn Screening Laboratory Network (UKNSLN) and more societies are affiliated with IJNS. Societies members receive discounts on the article processing charges.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.
  • Journal Rank: JCR - Q1 (Pediatrics) / CiteScore - Q1 (Pediatrics, Perinatology and Child Health)
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 29.8 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (754)

  • Feature Paper
  • Article
  • Open Access

Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder most commonly caused by 21-hydroxylase deficiency and can lead to life-threatening adrenal crises in infancy if not detected early. In Pakistan, the true incidence of CAH remains unknown due to the absence of national newborn screening programs. This study evaluated the effectiveness of a CAH newborn screening program introduced in 2021 at tertiary and secondary care centers in Pakistan. A retrospective cohort analysis included newborns screened between January 2021 and August 2025 using dried blood spot (DBS) 17-hydroxyprogesterone (17-OHP) testing. During the study period, 39,729 live births occurred, of which 34,621 newborns (87.1%) underwent screening. A total of 189 infants (0.55%) screened positive. Five infants were confirmed to have salt-wasting CAH; three, identified through population-based screening alone, yielded an incidence of 7.6 per 100,000 live births. The positive predictive value was 2.65%, reflecting a high false-positive rate, particularly among premature infants, while no false-negative cases were identified during the available follow-up period. This study demonstrates the feasibility of CAH newborn screening in a resource-limited setting and provides the first incidence estimates from a Pakistani hospital cohort.

Initial CAH screening protocol.
  • Comment
  • Open Access

Given the substantial morbidity of congenital cytomegalovirus (cCMV) infection on child health, there is considerable interest in the question of whether every newborn infant should be screened for this infection, toward the goal of identifying infants that may benefit from early intervention, anticipatory monitoring, and (in some cases) antiviral therapy [...]

Int. J. Neonatal Screen.

12 November 2026

  • Article
  • Open Access

Krabbe disease (KD) is a rare, inherited leukodystrophy associated with early mortality. Infantile Krabbe disease (IKD) was added to the Recommended Uniform Screening Panel (RUSP) in July 2024. Since then, U.S. states have continued to evaluate implementing KD newborn screening (NBS), and RUSP inclusion has hastened adoption efforts. This study aimed to characterize NBS program responses to this recommendation and identify factors influencing adoption and implementation. A mixed-methods approach was used, including a case review of Wisconsin’s process to add conditions to its NBS panel and a cross-sectional survey of U.S. NBS programs. Responses were obtained from 50 of 51 NBS programs. Twenty-two programs actively screen for KD, with ten additional programs in the implementation process. Screening approaches varied, particularly in psychosine (PSY) cutoff thresholds and testing algorithms. Programs reported a range of adoption pathways, including legislative mandates, advisory committee review, and state-specific nomination processes. Key factors impacting KD NBS adoption included uncertainty regarding treatment safety, efficacy, and availability, ethical considerations related to identifying later-onset disease, and logistical challenges such as laboratory readiness and clinical follow-up resources. This study provides a contemporary overview of national implementation of KD NBS and offers practical insights for programs considering adoption.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Int. J. Neonatal Screen. - ISSN 2409-515X